Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

Transcription profiling by array of human DA-MB-231 breast cancer cells treated with various SCFA-hexosamine analogs

ABSTRACT: The purpose of this study was to characterize the gene expression profile of MDA-MB-231 breast cancer cells treated with various SCFA-hexosamine analogs to better understand the role of various modifications to this scaffold. Experiment Overall Design: In total, six analogs were investigated in this study. For the relatively ""toxic"" C6-SCFA analogs, IC30 was selected to explore initial growth inhibitory and apoptotic gene expression changes. Two independent biological replicates were analyzed for each analog-treated condition. Three independent biological replicates were analyzed for the vehicle-treated control (EtOH).

ORGANISM(S): Homo sapiens

SUBMITTER: Kevin Yarema

PROVIDER: E-GEOD-11407 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Publications

Hexosamine template. A platform for modulating gene expression and for sugar-based drug discovery.

Elmouelhi Noha N Aich Udayanath U Paruchuri Venkata D P VD Meledeo M Adam MA Campbell Christopher T CT Wang Jean J JJ Srinivas Raja R Khanna Hargun S HS Yarema Kevin J KJ

Journal of medicinal chemistry 20090401 8

This study investigates the breadth of cellular responses engendered by short chain fatty acid (SCFA)-hexosamine hybrid molecules, a class of compounds long used in "metabolic glycoengineering" that are now emerging as drug candidates. First, a "mix and match" strategy showed that different SCFA (n-butyrate and acetate) appended to the same core sugar altered biological activity, complementing previous results [Campbell et al. J. Med. Chem. 2008, 51, 8135-8147] where a single type of SCFA elicit ...[more]

PMID: 19326913

Similar Datasets

Project description:Fifty percent of cutaneous melanomas are driven by activated BRAFV600E, but tumors treated with RAF inhibitors, even when they respond dramatically, rapidly adapt and develop resistance. Thus, there is a pressing need to identify the major mechanisms of intrinsic and adaptive resistance and develop drug combinations that target these resistance mechanisms. In a combinatorial drug screen on a panel of 12 treatment-naïve BRAFV600E mutant melanoma cell lines of varying levels of resistance to MAPK pathway inhibition we identified the combination PLX4720, a targeted inhibitor of mutated BRaf, and lapatinib, an inhibitor of the ERBB family of receptor tyrosine kinases, as synergistically cytotoxic in the subset of cell lines that displayed the most resistance to PLX4720. To identify potential mechanisms of resistance to PLX4720 treatment and synergy with lapatinib treatment we performed a multi-platform functional genomics analysis to profile the genome as well as the transcriptional and proteomic responses of these cell lines to treatment with PLX4720. We found modest levels of resistance correlated with the zygosity of the BRAF V600E allele and RTK mutational status. Layered over base-line resistance was substantial upregulation of many ERBB pathway genes in response to BRaf inhibition, thus generating the vulnerability to combination with lapatinib. The transcriptional responses of ERBB pathway genes are associated with a number of transcription factors, including ETS2 and its associated cofactors that represent a convergent regulatory mechanism conferring synergistic drug susceptibility in the context of diverse mutational landscapes. 12 BRAF mutant melanomas and 4 melanomas with WT BRAF were exposed plx4720 treatment to evaluate their responses after 8 hours of treatment. 5 of the 12 BRAF mutant melanomas responses were also evaluated in response to the treatment of lapatinib alone, masitinib alone, the combination of lapatinib with plx4720, or the combination of masitinib with plx4720. All samples were run in at least triplicate.

Project description:Neuronal cells are competent in precisely sensing nanotopographical features of their microenvironment and the intrinsic information impacts on neuronal functioning and differentiation “interpreted” by mechanotransductive processes. Attempts to influence and direct neuronal differentiation behaviour by engineering substrates that mimic appropriate extracellular matrix (ECM) topographies are hampered by the difficulty since many details of mechanosensing/-transduction are still elusive. Introducing omics methods into these biomaterial approaches has the potential to provide a deeper insight into the molecular processes and signalling cascades underlying mechanosensing/-transduction but their exigence in cellular material is often opposed by technical limitations of the biomaterial fabrication methods. Supersonic cluster beam deposition (SCBD) of zirconia nanoparticles allows instead the realisation of large macroscopic areas with biocompatible nanostructured films equipped with controllable and reproducible ECM-like nanoroughness that have been recently shown to foster neuron differentiation and maturation. Exploiting this capacity of SCBD, we challenged mechanosensing/-transduction and differentiative behaviour of neuron-like PC12 cells interacting with diverse nanotopographies and/or by changing their biomechanical status, to analyse their phosphoproteomic profiles in these settings. Versatile proteins were found to be affected that can be associated to significant processes along the mechanotransductive signal sequence, i.e. cell/cell interaction, glycocalyx and ECM, membrane/f-actin linkage and integrin activation, cell/substrate interaction, IAC, actomyosin organisation/cellular mechanics, nuclear organisation and transcription. The phosphoproteomic data suggested furthermore an involvement of ILK, mTor, Wnt and calcium signalling in these nanotopography- and/or cell mechanics-related processes. Altogether, potential nanotopography-sensitive, mechanotransductive signalling hubs participating to neuronal differentiation were dissected.

Dataset Information

Transcription profiling by array of human DA-MB-231 breast cancer cells treated with various SCFA-hexosamine analogs

Publications

Hexosamine template. A platform for modulating gene expression and for sugar-based drug discovery.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets